Literature DB >> 21046759

[Influence of astragalosides and Panax notoginseng saponins compatibility on MMP-9 and TIMP-1 after cerebral ischemia-reperfusion in mice].

Xiaoping Huang1, Hua Tan, Beiyang Chen, Changqing Deng.   

Abstract

OBJECTIVE: To investigate the effect of astragalosides (AST) and Panax notoginseng saponins (PNS) compatibility on the expression of matrix metalloproteinases-9 (MMP-9) and tissue inhibitor of metal11oproteinase-1 (TIMP-1) after cerebral ischemia/reperfusion (I/R) injury in mice, to probe into its anti-ischemic brain injury protection mechanism.
METHOD: C57BL/6N mice were randomly divided into sham-operation group, model group, AST and PNS compatibility of high, medium and low-dose group, AST group, PNS group and edaravone group. Cerebral ischemia-reperfusion injury were prepared by bilateral common carotid artery ligation for 20 min followed by 24 hours reperfusion after administration for 4 days. Pathomorphism was detected with HE staining and the expression of MMP-9 and TIMP-1 protein in brain was detected by western-blot. RESULT: The neuronal survival rate in the drug groups was significantly higher than the control group (P < 0.01), and the effect of the-middle dose compatibility group was more obvious. Factorial analysis manifested that AST110 mg x kg(-1) and PNS115 mg x kg(-1) compatibility had a synergistic interaction (P < 0.01). The expression of MMP-9 protein in the drug groups was lower than the model group significantly (P < 0.01 or P < 0.05), but the expression of TIMP-1 protein was higher than the model group significantly (P < 0.01 or P < 0.05), and the effect of the-middle dose compatibility group was more obvious, the two drugs had the stacking interaction (P < 0.05).
CONCLUSION: AST110 mg x kg(-1) and PNS115 mg x kg(-1) compatibility has a synergistic effect against ischemia-reperfusion injury in mice by accommodating MMP-9/TIMP-1 probably.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21046759

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  8 in total

1.  Exploring mechanisms of Panax notoginseng saponins in treating coronary heart disease by integrating gene interaction network and functional enrichment analysis.

Authors:  Gui Yu; Jie Wang
Journal:  Chin J Integr Med       Date:  2016-05-16       Impact factor: 1.978

2.  Vascular protective effects of Astragalus membranaceus and its main constituents in rats with chronic hyperhomocysteinemia.

Authors:  Li-Hong Qiu; Bi-Qi Zhang; Miao-Jun Lian; Xian-Ji Xie; Peng Chen
Journal:  Exp Ther Med       Date:  2017-07-09       Impact factor: 2.447

3.  Anti-inflammatory effects of Chinese medicinal herbs on cerebral ischemia.

Authors:  Shan-Yu Su; Ching-Liang Hsieh
Journal:  Chin Med       Date:  2011-07-09       Impact factor: 5.455

4.  Role of glyco-persica(®) in targeting diabetes type 2: an integrative approach.

Authors:  Mehrab Dashtdar; Mohammad Reza Dashtdar; Babak Dashtdar; Saeed Ahmad Khan
Journal:  J Pharmacopuncture       Date:  2013-12

5.  Effect of Liuweibuqi capsules on the balance between MMP-9 and TIMP1 and viability of alveolar macrophages in COPD.

Authors:  Chengyang Wang; Huanzhang Ding; Xiao Tang; Zegeng Li; Lei Gan
Journal:  Biosci Rep       Date:  2017-09-19       Impact factor: 3.840

6.  Effects of the main active components combinations of Astragalus and Panax notoginseng on energy metabolism in brain tissues after cerebral ischemia-reperfusion in mice.

Authors:  Xiao-Ping Huang; Huang Ding; Bei Wang; Yong-Yuan Qiu; Ying-Hong Tang; Rong Zeng; Chang-Qing Deng
Journal:  Pharmacogn Mag       Date:  2015 Oct-Dec       Impact factor: 1.085

Review 7.  Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage.

Authors:  Kai Sun; Jingyu Fan; Jingyan Han
Journal:  Acta Pharm Sin B       Date:  2015-01-24       Impact factor: 11.413

8.  Liuweibuqi capsules improve pulmonary function in stable chronic obstructive pulmonary disease with lung-qi deficiency syndrome by regulating STAT4/STAT6 and MMP-9/TIMP-1.

Authors:  Dan-Dan Shen; Zhong-Hui Yang; Ji Huang; Fei Yang; Zi-Wei Lin; Ying-Fei Ou; Min-Hao Hu
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.